HBM UCITS (Lux) Funds - HBM Global Biotechnology Fund P Cap USDRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 18.2 | -3.3 | -0.9 | 6.5 | 3.4 | |
+/-Cat | -7.8 | 5.8 | 6.9 | 7.8 | 1.1 | |
+/-B’mrk | -14.7 | -3.6 | -3.4 | -0.8 | -5.1 | |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 24/04/2024 | USD 435.35 | |
Day Change | -0.62% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU1540962054 | |
Fund Size (Mil) 24/04/2024 | USD 23.13 | |
Share Class Size (Mil) 24/04/2024 | USD 19.27 | |
Max Initial Charge | 3.00% | |
Ongoing Charge 19/02/2024 | 1.77% |
Investment Objective: HBM UCITS (Lux) Funds - HBM Global Biotechnology Fund P Cap USD |
The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Ivo Staijen 31/12/2011 | ||
Inception Date 06/09/2017 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for HBM UCITS (Lux) Funds - HBM Global Biotechnology Fund P Cap USD | 31/12/2023 |
|
|
Top 5 Holdings | Sector | % |
Cytokinetics Inc | Healthcare | 6.62 |
Amgen Inc | Healthcare | 5.71 |
Vertex Pharmaceuticals Inc | Healthcare | 5.65 |
Regeneron Pharmaceuticals Inc | Healthcare | 5.22 |
Neurocrine Biosciences Inc | Healthcare | 3.92 |
Increase Decrease New since last portfolio | ||
HBM UCITS (Lux) Funds - HBM Global Biotechnology Fund P Cap USD |